029 Group SE

Earnings Release • Aug 23, 2005

News Details

Ad-hoc | 23 August 2005 07:14

Rhein Biotech N.V. reports Half Year Results 2005

Ad hoc announcement §15 WpHG Half Year Results 2005 Rhein Biotech N.V. reports Half Year Results 2005 Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Maastricht, August 23, 2005 Rhein Biotech N.V. reports Half Year 2005 net sales of 10.3 million Euro. The EBITDA was -1.6 million Euro, while the loss from operations (EBIT) was – 5.9 million Euro. Rhein Biotech’s net loss in the Half Year 2005 amounted to -5.1 million Euro. The company’s cash position at the end of June 2005 was 23 million Euro. On January 1, 2005 the Korean subsidiary GreenCros Vaccine Corp. sold its assets related to four Korean vaccine products, DTP, Japanese Encephalitis, Varicella and Hantavax, which also lead to a transfer of 73 staff members dedicated to those four products. The assets transfer underlines the strategic focus on the Hepatitis B franchise and the combination vaccines. The assets transfer is the main reason for the decrease in net sales of 21% compared with the first half year 2004. Consolidated income statement for the half year ending June 30, 2005 Dutch GAAP; The results are unaudited. Amounts in EUR ‘000.: 2005 / 2004 Net sales: 10’310 / 13’128 Loss from operations (EBIT): -5 948 / -2’863 Financial result, net: 251 / 53 Other income: -326 / 17 Loss before taxes: -6’023 / -2’793 Taxes: 789 / -86 Minority interests: 88 / 383 Consolidated net loss: -5’146 / -2’496 Income from operations before depreciation (EBITDA): -1’625 / 1’739 Rhein Biotech N.V. Gaetano Martinolaan 95 6229 GS Maastricht Netherlands ISIN: NL0000230324 WKN: 919544 Listed: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart End of ad hoc announcement (c)DGAP 23.08.2005 230714 Aug 05